Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21
Filtrar
1.
J Clin Oncol ; 5(3): 354-64, 1987 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-3819804

RESUMEN

Fifty-nine evaluable patients under 65 years of age with measurable metastatic breast cancer and without prior chemotherapy were randomly assigned to treatment with fluorouracil, Adriamycin (Adria Laboratories, Columbus, OH), and cyclophosphamide (FAC) at standard or high doses (100% to 260% higher than standard FAC) following a dose escalation schedule. Patients randomized to the high-dose FAC received the first three cycles of therapy within a protected environment. Subsequent cycles for this group were administered at standard doses of FAC in an ambulatory setting, the same as for the control group. After reaching 450 mg/m2 of Adriamycin, patients in both groups continued treatment with cyclophosphamide, methotrexate, and fluorouracil until there was disease progression. Analysis of pretreatment patient characteristics showed an even distribution for most known pretreatment factors, although the control group had slightly (but nonsignificantly) more favorable prognostic characteristics. Fourteen patients (24%) achieved a complete remission (CR) and 32 (54%) achieved a partial remission (PR), for an overall major response rate of 78%. There were no differences in overall, CR, or PR rates between the high-dose FAC and control groups. The median response durations were 11 and 10 months for the protected environment and control groups, respectively, and the median survival was 20 months for both groups. Hematologic, gastrointestinal (GI), and infection-related complications were significantly more frequent and severe in the group treated with high-dose chemotherapy. Stomatitis, diarrhea, and skin toxicity were dose-limiting. However, there were no treatment-related deaths. High-dose induction combination chemotherapy with the agents used in this study failed to increase the response rate or survival duration, and resulted in a substantial increase in toxicity.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Ciclofosfamida/administración & dosificación , Doxorrubicina/administración & dosificación , Evaluación de Medicamentos , Femenino , Fluorouracilo/administración & dosificación , Humanos , Persona de Mediana Edad , Metástasis de la Neoplasia , Estudios Prospectivos , Distribución Aleatoria , Riesgo
2.
J Clin Oncol ; 5(2): 178-84, 1987 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-3543241

RESUMEN

To test the hypothesis of whether high doses of chemotherapy in combination achieve higher response rates and longer durations of response and survival, we treated 33 pre- and perimenopausal patients with good performance status in a prospective trial with escalating doses of fluorouracil, doxorubicin and cyclophosphamide (FAC). Patients were randomly assigned to be treated within a protected environment (laminar air flow room), with prophylactic antibiotics, or in a standard hospital room. Important patient characteristics were equally distributed in the two treatment arms. A major objective response was observed in 27 of the 32 evaluable patients (84%), and 11 (34%) achieved a complete remission (CR). There was no significant difference in overall and complete response rates between the two treatment arms, nor was there a substantial difference in times to progression or survival between the groups treated in or out of the protected environment. Comparison of the results of this study with previously reported programs of FAC chemotherapy in patients with metastatic breast cancer shows that this study achieved higher overall and complete response rates. However, neither the time to progression, nor the survival of responders or the entire patient group was different from our previous experience with standard FAC chemotherapy. When the study was initiated in 1976, the proposed dose escalation represented high-dose chemotherapy. In retrospect, even the "high" doses used in this study represent only a modest increase over standard doses of chemotherapy. Much steeper dose escalations will be needed to evaluate the efficacy of high-dose chemotherapy in breast cancer, as well as the protective value of the protected environment and prophylactic antibiotics in metastatic breast cancer.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Ambiente Controlado , Adulto , Antibacterianos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Neoplasias de la Mama/mortalidad , Ensayos Clínicos como Asunto , Ciclofosfamida/administración & dosificación , Doxorrubicina/administración & dosificación , Femenino , Fluorouracilo/administración & dosificación , Humanos , Persona de Mediana Edad , Premedicación , Estudios Prospectivos , Distribución Aleatoria , Inducción de Remisión , Factores de Tiempo
3.
Am J Clin Oncol ; 9(3): 269-75, 1986 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-3755282

RESUMEN

Between 1974 and 1982, 797 patients who had operable breast cancer were treated at the University of Texas M.D. Anderson Hospital and Tumor Institute at Houston with three adjuvant chemotherapy trials consisting of fluorouracil, doxorubicin, and cyclophosphamide (FAC). The incidence of second primary malignant tumors in this group of patients was evaluated and compared with that in a historical control group of patients who had stages II and III disease (n = 186) and who did not receive adjuvant chemotherapy following surgery. Radiotherapy was given to 54% (n = 433) of the chemotherapy-treated patients and to 96% (n = 178) of the controls. The median age of the patients was 49.6 and 55 years for the treated and control groups, respectively. Second neoplasms developed in 10 chemotherapy-treated patients and in nine control patients; rates at 5 years from initiation of therapy based on actuarial curves were 1.9 and 5.0%, respectively. These second tumors developed after a median latency period of 17.5 months for the FAC-treated group and 13 months for the controls. Two cases of leukemia developed in each of the two treatment groups. The rate of second malignancy in the chemotherapy-treated patients was not increased compared with that in the historical controls.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias Primarias Múltiples/epidemiología , Adulto , Factores de Edad , Anciano , Neoplasias de la Mama/cirugía , Ciclofosfamida/uso terapéutico , Doxorrubicina/uso terapéutico , Femenino , Fluorouracilo/uso terapéutico , Humanos , Leucemia/epidemiología , Persona de Mediana Edad , Factores de Tiempo
4.
Cancer ; 55(12): 2761-5, 1985 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-3922612

RESUMEN

Five hundred thirty-four evaluable patients with breast cancer were treated with a combination of 5-fluorouracil, doxorubicin, and cyclophosphamide. The total planned dose of doxorubicin was 300 mg/m2 in patients with Stage II or III disease, and 450 mg/m2 in patients with isolated recurrences. The median time interval from start of adjuvant therapy to time of analysis was 68 months. Two percent had congestive heart failure associated with doxorubicin. Fifteen patients showed myocardial dysfunction attributed to either additional treatment with potentially cardiotoxic drugs for recurrent disease or other causes. The incidence of congestive heart failure was 1% in patients treated with up to 300 mg/m2, and 4% in patients who received 450 mg/m2 of doxorubicin. The median time interval from the end of doxorubicin to development of congestive heart failure was 1 month (range, 0-33 months). None of the 326 patients who have been followed 3 or more years (162 followed 5 or more years) since completion of doxorubicin therapy have developed congestive heart failure which was considered to be related from that therapy.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Doxorrubicina/efectos adversos , Cardiopatías/inducido químicamente , Adulto , Anciano , Antraquinonas/efectos adversos , Cardiomiopatías/inducido químicamente , Ciclofosfamida/administración & dosificación , Relación Dosis-Respuesta a Droga , Doxorrubicina/administración & dosificación , Fluorouracilo/administración & dosificación , Estudios de Seguimiento , Insuficiencia Cardíaca/inducido químicamente , Humanos , Persona de Mediana Edad , Mitomicina , Mitomicinas/efectos adversos , Mitoxantrona , Recurrencia Local de Neoplasia/tratamiento farmacológico , Riesgo , Factores de Tiempo
5.
Cancer Res ; 44(3): 923-8, 1984 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-6692414

RESUMEN

The use of normal bone marrow (granulocyte-macrophage colony-forming units) as a point of reference to normalize the in vitro activities of anticancer agents has been investigated. The cytotoxic effects of four substituted anthraquinone derivatives, and of vinblastine on myeloid progenitors of different donors were reproducible up to a cell kill of approximately 60%. Equitoxic in vitro concentrations for normal bone marrows did not correlate with in vivo pharmacokinetic concentrations of these drugs. Breast tumor progenitor cells of 46 specimens were more sensitive than were bone marrow progenitors to the anthraquinone derivatives in 26 to 39% of instances, ratios which are similar to the clinically observed response rates of patients with breast carcinoma to these agents. Tumors were either sensitive or resistant to all four drugs in 68% (10 tumors were more sensitive, and 21 tumors were less sensitive than normal bone marrow); but in 32% of instances there were differences in tumor sensitivity for the four drugs, and the assay could select one to three drugs for which the tumor sensitivity was greater than that of bone marrow. Correlations of in vitro sensitivity and of clinical response to single agent treatments were determined in 21 patients, and the concordance was 71%. The value of the assay in predicting clinical response ranked best for sensitivity determinations within the normalized dose ranges, when testing within three different dose ranges was compared in a group of six patients. The concordance was higher in the small (1 or 2 metastatic sites) than in the large (greater than or equal to 3 metastatic sites) tumors (85 versus 50%), indicating a confounding influence of tumor load on the ability of the assay to predict efficacy of treatment. A rule of thumb is proposed for altering the in vitro sensitivity test results for large tumors that improves the overall concordance to 90%.


Asunto(s)
Antineoplásicos/toxicidad , Médula Ósea/fisiología , Neoplasias de la Mama/fisiopatología , Médula Ósea/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Células Clonales , Ensayo de Unidades Formadoras de Colonias , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos/métodos , Femenino , Células Madre Hematopoyéticas/efectos de los fármacos , Células Madre Hematopoyéticas/fisiología , Humanos , Cinética
6.
Cancer ; 53(3): 384-9, 1984 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-6362814

RESUMEN

Between May 1977 and April 1980, 238 patients with operable breast cancer were treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) chemotherapy. All patients were randomized to receive FAC alone or FAC with nonspecific immunotherapy with Bacillus Calmette-Guerin (BCG) vaccine. A randomization for routine postoperative irradiation was included in the study in May 1978. At the median follow-up of 33 months, 53 patients had developed recurrent disease. Up to the present time, there have been no significant differences in the disease-free survival of patients treated with FAC alone from those treated with FAC + BCG (P = 0.21). The disease-free survival for patients treated with and without routine postoperative irradiation was similar (P = 0.99). Disease-free survival of premenopausal and postmenopausal women was similar. The overall estimate of disease-free survival was 72% at 3 years.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Vacuna BCG/uso terapéutico , Neoplasias de la Mama/terapia , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/radioterapia , Neoplasias de la Mama/cirugía , Ensayos Clínicos como Asunto , Terapia Combinada , Ciclofosfamida/administración & dosificación , Doxorrubicina/administración & dosificación , Femenino , Fluorouracilo/administración & dosificación , Humanos , Persona de Mediana Edad , Estudios Prospectivos , Distribución Aleatoria
9.
Int J Radiat Oncol Biol Phys ; 9(5): 643-50, 1983 May.
Artículo en Inglés | MEDLINE | ID: mdl-6343312

RESUMEN

Fifty-two patients with locally advanced primary breast cancer (T3, T4, N2, N3) but no evidence of distant metastases were treated with three cycles of combination chemotherapy. The regimen consisted of 5-fluorouracil, Adriamycin, cyclophosphamide, and Bacillus Calmette-Guerin (FAC-BCG), followed by local therapy (simple mastectomy and/or radiotherapy to the breast/chest wall and the regional lymphatic system) and adjuvant chemotherapy for two full years. The results were compared with those in an historical control group of 52 patients matched for initial stage of disease who were treated by a simple mastectomy and postoperative radiotherapy only. Forty-nine (94%) of 52 FAC-treated patients and 48 (92%) of the control patients became free of clinically detectable disease. At the median follow-up time of 56 months, 37.5% of the FAC-treated patients and 19.5% of the control patients had remained free of disease. FAC-treated patients who completed 2 years of therapy and in whom adjuvant chemotherapy was started promptly after local treatment had a 48% disease-free survival rate of 4 years. In those in whom the initial manifestation was supraclavicular involvement, the estimated 5-year disease-free survival rate was 42% for patients treated with FAC and 9% for control patients. There were local recurrences in 25% of FAC-treated patients and 23% of control patients (not significant). Distant metastases developed in 50% of FAC-treated patients and 77% of control patients (p less than 0.01). The median disease-free interval was 25 months in the FAC-treated group and 11 months in the control group (p = 0.025). The greatest improvement in prognosis was in patients with supraclavicular involvement; the median disease-free survival was 26 months in FAC-treated patients and 6 months in the control group (p = 0.007). This multimodal approach effectively renders the majority of patients with locoregionally advanced breast cancer free of disease and prolongs the disease-free survival period.


Asunto(s)
Antineoplásicos/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica , Vacuna BCG/administración & dosificación , Neoplasias de la Mama/terapia , Adulto , Anciano , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/mortalidad , Neoplasias de la Mama/radioterapia , Neoplasias de la Mama/cirugía , Ensayos Clínicos como Asunto , Ciclofosfamida/administración & dosificación , Doxorrubicina/administración & dosificación , Quimioterapia Combinada , Femenino , Fluorouracilo/administración & dosificación , Humanos , Mastectomía , Metotrexato/administración & dosificación , Persona de Mediana Edad
10.
J Surg Oncol ; 23(1): 32-4, 1983 May.
Artículo en Inglés | MEDLINE | ID: mdl-6687746

RESUMEN

Included in this study were 43 breast cancer patients treated with adjuvant chemotherapy who presented metastasis only in bone. Forty-two percent had metastasis during chemotherapy, and 58% had metastasis after the completion of chemotherapy. In 66% of the patients, the lesions were osteolytic. Twenty-nine percent had osteoblastic lesions, and 5% had mixed lesions. Of the patients with osteoblastic metastatic disease, five showed asymptomatic, osteoblastic disease; this response was considered to be a healing response to chemotherapy. These five patients were continued on the same therapy. The median duration of this response to the adjuvant chemotherapy was 29 months (range 6 to 62+). In one patient, osteoblastic disease gradually faded, and skeletal radiographs reverted to normal.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica , Neoplasias Óseas/secundario , Neoplasias de la Mama/tratamiento farmacológico , Ciclofosfamida/efectos adversos , Doxorrubicina/efectos adversos , Fluorouracilo/efectos adversos , Adulto , Anciano , Neoplasias de la Mama/cirugía , Quimioterapia Combinada , Femenino , Humanos , Mastectomía , Persona de Mediana Edad
11.
Cancer ; 51(5): 763-8, 1983 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-6687377

RESUMEN

Fifty-two patients with locally advanced primary breast cancer (T3, T4/N2, N3) without distant metastases were treated with three cycles of combination chemotherapy consisting of 5-FU, Adriamycin and cyclophosphamide (FAC) and immunotherapy with Bacillus Calmette-Guerin (BCG) followed by local therapy (simple mastectomy and/or radiotherapy to breast/chest wall and regional lymphatics) and adjuvant chemotherapy to complete two years of treatment. Forty-nine of 52 (94%) patients were rendered free of clinically detectable disease. The median disease-free interval was 24 months. At a median follow-up time of 60 months, 40% of patients remained free of disease, off all therapy. Those patients who completed two years of therapy and started adjuvant chemotherapy promptly after local treatment had a 48% disease-free survival at five years. Local recurrences were observed in 21% of patients. Distant metastases developed in 40% of patients. Despite good tolerance, treatment compliance was poor. The complete remission rate with this multimodal approach is high and long-term disease-free survival is achieved in a considerable number of patients.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica , Vacuna BCG/uso terapéutico , Neoplasias de la Mama/terapia , Ciclofosfamida/administración & dosificación , Doxorrubicina/administración & dosificación , Fluorouracilo/administración & dosificación , Metotrexato/administración & dosificación , Adulto , Anciano , Quimioterapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Persona de Mediana Edad , Metástasis de la Neoplasia , Recurrencia Local de Neoplasia , Pronóstico
12.
Breast Cancer Res Treat ; 2(2): 163-9, 1982.
Artículo en Inglés | MEDLINE | ID: mdl-6897369

RESUMEN

Four hundred and sixty patients with stage II or III breast cancer following regional therapy were treated with an adjuvant combination chemotherapy consisting of fluorouracil, doxorubicin, and cyclophosphamide (FAC). The relationship between the length of disease-free survival and length of delays in initiation of chemotherapy after surgery was evaluated. Patients were divided into four subgroups according to the length of delay in initiation of chemotherapy (less than 10 weeks, 10-13, 14-17, and greater than or equal to 18 weeks). Overall four year disease-free survival was 64%, 68%, 60%, and 63% for patient groups with delays of less than 10 weeks, 10-13, 14-17, or greater than or equal to 18 weeks respectively (p = 0.39). There was no trend for longer delay in treatment to be associated with shorter disease-free survival, except in poor prognosis patients.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica , Neoplasias de la Mama/terapia , Ciclofosfamida/administración & dosificación , Doxorrubicina/administración & dosificación , Fluorouracilo/administración & dosificación , Adulto , Vacuna BCG/uso terapéutico , Neoplasias de la Mama/mortalidad , Esquema de Medicación , Quimioterapia Combinada , Femenino , Humanos , Mastectomía , Persona de Mediana Edad , Pronóstico , Factores de Tiempo
13.
Cancer ; 47(12): 2798-802, 1981 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-7260870

RESUMEN

Sixty-two patients with breast cancer treated with Adriamycin-containing adjuvant chemotherapy developed recurrent disease. Four patients refused to take any form of systemic therapy at the time of relapse. Fifty-eight patients were managed with various treatment modalities, and of these 33 (57%) achieved on objective remission, 11 (19%) had stable disease and 14 patients (24%) did not respond to any form of therapy. Twenty-four patients received more than one treatment modality. Thirty-eight patients were treated with chemotherapy and 35 received endocrine therapy. Eight of 20 patients (40%) achieved objective remission upon retreatment with higher dose of 5-fluorouracil, Adriamycin, and cyclophosphamide at time of relapse, and seven of 18 patients (38%) treated with other chemotherapeutic agents showed objective remission. Fourteen of 35 patients (40%) achieved objective remission with hormonal therapies. The median survival from first relapse was 15 months for all patients, and was 25.7 months for responding patients. Survival was significantly longer in asymptomatic patients compared with those who were symptomatic from recurrent disease.


Asunto(s)
Antineoplásicos/administración & dosificación , Neoplasias de la Mama/terapia , Doxorrubicina/administración & dosificación , Recurrencia Local de Neoplasia/terapia , Adulto , Anciano , Neoplasias de la Mama/mortalidad , Castración , Ciclofosfamida/administración & dosificación , Esquema de Medicación , Quimioterapia Combinada , Femenino , Fluorouracilo/administración & dosificación , Humanos , Persona de Mediana Edad , Tamoxifeno/administración & dosificación
14.
J Surg Oncol ; 18(2): 163-72, 1981.
Artículo en Inglés | MEDLINE | ID: mdl-7300363

RESUMEN

In an attempt to prolong the durations of remission and survival of patients with advanced breast cancer treated with the FAC-BCG protocol, we modified the CMF maintenance combination by increasing the dose of all three drugs and administering them intravenously. Eighty-five evaluable patients treated with this new regimen were compared with a recent historical control group of 105 evaluable patients treated with FAC-BCG and a lower-dose, oral CMF maintenance program. The overall (70% and 76%) and complete (16% and 19%) response rates were identical in these two groups. The median times to progression for all patients entered were similar too (13 months for both groups.). The durations of response were 17 months (PO-CMF) and 14 months (IV-CMF), not significantly different (P = .16). The durations of survival of the two treated groups were also very similar. After the administration of intensive FAC induction therapy, a high-dose, intravenous CMF maintenance program appears no better than a low-dose oral regimen. Other drug combinations consisting entirely of drugs not used in the induction regimen might be better choices for maintenance treatment


Asunto(s)
Antineoplásicos/administración & dosificación , Vacuna BCG/uso terapéutico , Neoplasias de la Mama/terapia , Administración Oral , Adulto , Anciano , Neoplasias de la Mama/patología , Ciclofosfamida/administración & dosificación , Doxorrubicina/administración & dosificación , Esquema de Medicación , Quimioterapia Combinada , Femenino , Fluorouracilo/administración & dosificación , Humanos , Inyecciones Intravenosas , Metotrexato/administración & dosificación , Persona de Mediana Edad , Metástasis de la Neoplasia
15.
JAMA ; 242(14): 1509-13, 1979 Oct 05.
Artículo en Inglés | MEDLINE | ID: mdl-470088

RESUMEN

Two hundred twenty-two patients with stage II or III breast cancer following regional therapy were treated with a combination of fluorouracil, doxorubicin hydrochloride (Adrimycin), cyclophosphamide, and BCG vaccine. At 54 months of study (median follow-up, 30 months), the estimated proportions remaining disease-free two and three years after surgery were 83%and 78%, respectively, in the chemotherapy group and 64% and 55%, respectively, in 151 historical control patients. Estimated two- and three-year survival rates were 93% and 89%, respectively, in the chemotherapy group and 84% and 58%, respectively, in the control patients. Congestive heart failure has developed in three patients, possibly related to the use of doxorubicin. Adjuvant chemotherapy with these drugs was effective in prolonging the disease-free interval and survival of patients irrespective of menopausal status, degree of nodal involvement, or stage of the disease.


Asunto(s)
Antineoplásicos/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Vacuna BCG/uso terapéutico , Neoplasias de la Mama/mortalidad , Neoplasias de la Mama/cirugía , Ciclofosfamida/uso terapéutico , Doxorrubicina/efectos adversos , Doxorrubicina/uso terapéutico , Quimioterapia Combinada , Femenino , Fluorouracilo/uso terapéutico , Insuficiencia Cardíaca/inducido químicamente , Humanos , Persona de Mediana Edad , Metástasis de la Neoplasia
16.
Cancer Treat Rep ; 63(5): 757-61, 1979 May.
Artículo en Inglés | MEDLINE | ID: mdl-313246

RESUMEN

High-dose infusions of methotrexate with citrovorum factor rescue were evaluated in 27 patients with advanced recurrent breast cancer who had previously been treated with various Adriamycin-containing regimens. Eight of 27 patients (29%) achieved objective tumor regression with a median duration of response of 26 weeks. Nineteen patients had previously received standard doses of methotrexate (less than 50 mg/m2/dose), while eight patients had had no prior exposure to methotrexate. The response rates observed in these two groups of patients were similar. Except for two drug-related deaths, toxic effects were acceptable. Myelosuppression was mild, transient, and noncumulative. Gastrointestinal toxic effects did not appear to be dose-related and were mild in most instances. Central nervous system dysfunction with lethargy, fatigability, confusion, and disorientation was the most significant toxic effect of this high-dose methotrexate therapy and was observed in six (22%) of the patients. In two patients treatment with this program was discontinued because of the development of renal dysfunction. High-dose methotrexate with citrovorum factor rescue appears to be an effective regimen in patients with advanced refractory breast cancer. However, in view of the enormous cost necessitated by this treatment approach, we do not feel further studies would be worthwhile.


Asunto(s)
Neoplasias de la Mama/tratamiento farmacológico , Metotrexato/uso terapéutico , Factores de Edad , Antineoplásicos/administración & dosificación , Recuento de Células Sanguíneas , Neoplasias de la Mama/patología , Quimioterapia Combinada , Femenino , Humanos , Leucovorina/administración & dosificación , Leucovorina/uso terapéutico , Metotrexato/administración & dosificación , Metotrexato/efectos adversos
17.
Cancer Treat Rep ; 63(5): 789-91, 1979 May.
Artículo en Inglés | MEDLINE | ID: mdl-455316

RESUMEN

A phase II evaluation of anguidine was carried out in 30 patients with advanced refractory breast cancer. A dose of 5.0 mg/m2 daily for 5 days was explored. The main toxic effects were nausea and vomiting, fever and chills, hypotension, skin erythema, somnolence, confusion, and lethargy. Myelosuppression was minimal. Among these extensively pretreated patients, there was one partial responder and one additional patient who showed improvement (less than a partial response); both responses occurred in soft tissue sites.


Asunto(s)
Antineoplásicos Fitogénicos/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Sesquiterpenos/uso terapéutico , Tricotecenos/uso terapéutico , Adulto , Anciano , Antineoplásicos Fitogénicos/efectos adversos , Neoplasias de la Mama/patología , Femenino , Fusarium , Humanos , Persona de Mediana Edad , Tricotecenos/efectos adversos
18.
J Surg Oncol ; 12(1): 27-40, 1979.
Artículo en Inglés | MEDLINE | ID: mdl-480951

RESUMEN

A combination of 5-fluorouracil, Adriamycin, cyclophosphamide, and BCG (FAC-BCG) was evaluated as adjuvant treatment in breast cancer patients following surgical excision and/or radiation of first site of recurrent disease. In a group of 68 patients treated with FAC-BCG, the estimated proportion remaining free of disease at 2 years from first recurrence was 69%, compared to 24% in 60 historical control patients (P less than 0.01). Estimated 2-year survival rate from first recurrence was 85% for the FAC-BCG patients and 78% for the controls (P = 0.07). This regimen has significantly prolonged the disease-free interval from the first recurrence, but additional follow-up is needed to determine its effect on long-term survival.


Asunto(s)
Antineoplásicos/administración & dosificación , Vacuna BCG/uso terapéutico , Neoplasias de la Mama/terapia , Neoplasias de la Mama/mortalidad , Ciclofosfamida/administración & dosificación , Doxorrubicina/administración & dosificación , Quimioterapia Combinada , Femenino , Fluorouracilo/administración & dosificación , Humanos , Inmunoterapia , Metástasis Linfática , Persona de Mediana Edad , Neoplasias Torácicas/secundario , Neoplasias Torácicas/terapia
19.
Cancer ; 41(6): 2084-7, 1978 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-418867

RESUMEN

One hundred thirty-one patients with operable breast cancer were treated with adjuvant chemoimmunotherapy consisting of 5-fluorouracil, adriamycin, cyclophosphamide, and BCG (FAC-BCG). Fifty-five of 131 patients were premenopausal of which 71% (38/55) became amenorrheic. To determine the mechanism of amenorrhea, we measured the immunoreactive serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and plasma estradiol (E2) before and after intravenous administration of luteinizing hormone-releasing hormone (LH-RH) in 11 unselected premenopausal patients who developed amenorrhea and 11 unselected patients who did not. Serum prolactin (PRL) levels were also measured before and after iv administration of thyrotropin-releasing hormone (TRH). Our results showed that patients who developed amenorrhea had abnormally high serum LH and FSH levels at basal and after LH-RH stimulation and low plasma estradiol. Serum PRL levels were normal. Patients who developed amenorrhea were older than those who did not, but their serum LH and FSH levels were also significantly higher and plasma estrogens were significantly lower than that found in 11 normal women with regular menses of the same age range. These results indicate that amenorrhea that develops in some patients with breast cancer after FAC-BCG therapy is a result of primary ovarian failure.


Asunto(s)
Amenorrea/etiología , Neoplasias de la Mama/fisiopatología , Ovario/fisiopatología , Hipófisis/fisiopatología , Adulto , Vacuna BCG/uso terapéutico , Neoplasias de la Mama/complicaciones , Neoplasias de la Mama/terapia , Ciclofosfamida/efectos adversos , Doxorrubicina/efectos adversos , Quimioterapia Combinada , Estradiol/sangre , Femenino , Fluorouracilo/efectos adversos , Hormona Folículo Estimulante/sangre , Hormona Liberadora de Gonadotropina/administración & dosificación , Humanos , Hormona Luteinizante/sangre , Prolactina/sangre , Hormona Liberadora de Tirotropina/administración & dosificación
20.
Cancer ; 41(3): 1064-75, 1978 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-638948

RESUMEN

For the past 34 months, a combination of 5-fluorouracil, adriamycin, cyclophosphamide, and BCG (FAC-BCG) was evaluated as adjuvant treatment in stage II and III breast cancer patients with positive axillary nodes. In the group of 131 patients receiving FAC-BCG, the estimated proportion remaining disease-free at 2 years from surgery was 91% compared to an estimated 69% in a group of 151 historical control patients (p less than .01). This advantage was statistically significant in all subgroups except for patients with primary tumor less than 3 cm and for patients with less than 4 positive nodes. Estimated 2-year survival rates were 9,6% for FAC-BCG patients and 86% for control (p = .02). Treatment was well tolerated. Adjuvant FAC-BCG seems effective in prolonging disease-free interval and early survival in patients with stage II and III breast cancer. Its long term efficacy will require longer follow-ups.


Asunto(s)
Neoplasias de la Mama/terapia , Adulto , Anciano , Vacuna BCG/efectos adversos , Vacuna BCG/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Ciclofosfamida/uso terapéutico , Doxorrubicina/uso terapéutico , Quimioterapia Combinada/efectos adversos , Estudios de Evaluación como Asunto , Femenino , Fluorouracilo/uso terapéutico , Estudios de Seguimiento , Humanos , Inmunoterapia , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Recurrencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA